BPC-157: mechanism, evidence, and why the rodent data doesn't cleanly transfer.
BPC-157 ("body protection compound") is a 15-amino-acid fragment of a larger protein found in human gastric juice. The rodent literature on soft-tissue, tendon, ligament, and GI-mucosal healing is unusually consistent; the human evidence is essentially absent. That gap — and what vendors do with it — is the whole story.
- Synthetic 15-mer derived from human gastric-juice protein BPC. Not found intact in circulation.
- Dozens of rodent studies (Sikiric lab, Zagreb) show accelerated soft-tissue healing, GI ulcer protection, and angiogenesis.
- Human RCTs: zero published, peer-reviewed, placebo-controlled trials as of 2026-04.
- FDA placed BPC-157 on the 503A "do not compound" list in 2023 and reiterated its stance in 2024.
- "Stable" (arginate / acetate salt) vs plain pentadecapeptide: labeling ambiguity is a vendor QC red flag.
- Typical research-vial sizing is 5 mg lyophilized; reconstitution math below.
What BPC-157 actually is
BPC stands for "body protection compound" — a larger protein isolated from human gastric juice by the Sikiric group at the University of Zagreb in the 1990s. BPC-157 is a synthetic 15-residue fragment (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular weight 1419.5 Da) that retains the reparative activity attributed to the parent compound in rodent models. It is not identical to any naturally circulating peptide and it does not correspond to a known mammalian gene product.
This matters for two reasons. First, no amount of "it's naturally occurring" vendor copy applies — BPC-157 itself is not. Second, pharmacology experiments consistently describe the compound as a synthetic stable analog, which is why you'll often see it marketed as "BPC-157 arginate" or "acetate salt" to flag that the peptide has been formulated to resist enzymatic degradation.
Mechanism, at the level the research supports
The proposed mechanism is not a single receptor. Rodent work implicates at least four parallel effects that together would explain the reported healing phenotype:
- Nitric oxide system modulation. BPC-157 appears to counteract both the L-arginine/NOS blockade (L-NAME) and overexpression (L-arginine excess) effects in rodent gastric and vascular models. Multiple papers from the Sikiric lab frame this as "NO-system interaction" rather than pure agonism.
- Angiogenic signaling. Increased VEGFR2 expression and new capillary formation at injury sites is a repeated finding (rat Achilles transection, rat colocolonic anastomosis models).
- Growth hormone receptor upregulation. Chang et al., 2011 (J. Orthop. Res.) reported increased GHR expression on rat tendon fibroblasts after BPC-157 exposure, offering a plausible upstream link to observed proliferation.
- Dopaminergic and serotonergic system effects. Behavioral and CNS-injury rodent models show interactions, suggesting effects beyond peripheral wound repair.
The rodent evidence, honestly
If you restrict a search to PubMed-indexed work on BPC-157, you get ~200+ publications, the overwhelming majority from the Sikiric group and collaborators. The body of work spans:
- Tendon transection / Achilles rupture healing (rat)
- Ligament healing (medial collateral ligament, rat)
- Skeletal muscle crush / laceration (rat)
- GI mucosal protection (NSAID-induced ulcer, alcohol-induced ulcer, rat)
- Colocolonic anastomosis healing (rat)
- Gut-brain axis effects in CNS injury / neurotransmitter-perturbation models
- Cardioprotection in various ischemia-reperfusion rat models
Two honest caveats. First, the literature is heavily concentrated in one lab — not a reason to dismiss it, but a reason independent replication matters more than usual. Second, the classic translation-gap problems apply: rodent tendon physiology is not human tendon physiology, the dose-per-kg relationships don't scale cleanly, and route of administration (intraperitoneal is common in rat studies) is not what a human researcher would use.
The human evidence — what's actually there
As of April 2026, there are no published, peer-reviewed, placebo-controlled randomized clinical trials of BPC-157 in humans. A frequently cited claim that "a Phase II trial ran in Croatia for inflammatory bowel disease" refers to work in the early 2000s that did not publish formal RCT results in the peer-reviewed literature; what exists is fragmentary and not a substitute for a published trial.
That is the single most important sentence on this page. Every BPC-157 vendor listing, every YouTube protocol video, every Reddit n-of-1 report — none of it is supported by published human RCT evidence. Treat any claim to the contrary as a red flag.
Regulatory status
In September 2023, the FDA included BPC-157 on the list of bulk drug substances that should not be used in compounding under section 503A of the FD&C Act. The stated concerns were (1) lack of human safety data, (2) identity and quality concerns with the bulk peptide, and (3) the absence of accepted specifications in any pharmacopoeia. The FDA reaffirmed this position in 2024.
Practical implication: in the United States, compounding pharmacies may no longer sell BPC-157 for human use. Research-chemical vendors that sell "BPC-157 for research use only" are operating under a different framework — the peptide is sold as a research chemical, not as a drug, and the vendor typically requires the buyer to acknowledge the RUO framing.
Reconstitution math (the part vendors won't clarify)
Research vials typically ship as 5 mg of lyophilized peptide. Researchers add bacteriostatic water (BAC water, 0.9% benzyl alcohol), swirl gently, and store refrigerated. The math that matters is how many units on a U-100 insulin syringe corresponds to how many micrograms of peptide. A worked example for a 5 mg vial reconstituted in 2 mL of BAC water:
| BAC water added | Concentration | Per IU (U-100 scale) | For ~250 mcg dose |
|---|---|---|---|
| 1 mL | 5000 mcg/mL | 50 mcg | 5 IU |
| 2 mL | 2500 mcg/mL | 25 mcg | 10 IU |
| 3 mL | 1667 mcg/mL | 16.7 mcg | 15 IU |
| 5 mL | 1000 mcg/mL | 10 mcg | 25 IU |
Points to flag. A U-100 insulin syringe is calibrated for 100 IU = 1 mL, so "10 IU" = 0.1 mL. Peptide stability after reconstitution is typically quoted as 2–3 weeks refrigerated for BPC-157, but this is based on vendor stability data and not independently confirmed by pharmacopoeia-level testing.
Vendor sourcing — what to look for
- Per-lot COA with HPLC purity (>98%). An MSDS is not a COA. A COA without a lot number or test date is a branded PDF, not a certificate.
- Mass-spec confirmation. Purity by HPLC without mass-spec identity confirmation means you may have a pure compound of the wrong sequence.
- Endotoxin testing (LAL assay) is not standard on RUO vials; its absence is normal but relevant if you're in a regulated research setting.
- Salt form disclosed. "BPC-157 arginate salt" vs "BPC-157 TFA salt" vs "BPC-157 acetate" matters for both weight-per-vial calculations and for regulatory context.
- Cold-chain shipping in summer months — BPC-157 lyophilized is reasonably stable at room temperature short-term, but prolonged heat during transit is a real QC risk.
Where to read further
Selected PubMed-indexed starting points (current as of 2026-04):
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr. Pharm. Des. 2011; 17(16).
- Chang CH, et al. "Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts." Molecules 2014; 19(11).
- Gwyer D, et al. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell Tissue Res. 2019; 377(2).
- FDA CDER. "List of Bulk Drug Substances Nominated for Use in Compounding." Updated 2024.